HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons

The review analyzes the potential advantages and problems associated with using HIF prolyl hydroxylase inhibitors as a treatment for COVID-19. HIF prolyl hydroxylase inhibitors are known to boost endogenous erythropoietin (Epo) and activate erythropoiesis by stabilizing and activating the hypoxia in...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Front Pharmacol
Egile Nagusiak: Poloznikov, Andrey A., Nersisyan, Stepan A., Hushpulian, Dmitry M., Kazakov, Eliot H., Tonevitsky, Alexander G., Kazakov, Sergey V., Vechorko, Valery I., Nikulin, Sergey V., Makarova, Julia A., Gazaryan, Irina G.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2021
Gaiak:
Pharmacology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7878396/
https://ncbi.nlm.nih.gov/pubmed/33584306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.621054
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak